{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:51:12Z","timestamp":1792036272902,"version":"4.4.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":778,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s13311-021-01073-y","type":"journal-article","created":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T15:02:31Z","timestamp":1625583751000},"page":"1657-1664","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Association Between Disease-Modifying Therapies Prescribed to Persons with Multiple Sclerosis and Cancer: a WHO Pharmacovigilance Database Analysis"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0449-6261","authenticated-orcid":false,"given":"Charles","family":"Dolladille","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basile","family":"Chr\u00e9tien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Peyro-Saint-Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Alexandre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Dejardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Fedrizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Defer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-021-01073-y_bib1","doi-asserted-by":"crossref","unstructured":"Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, et al. ECTRIMS\/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler J. :25.","DOI":"10.1111\/ene.13536"},{"key":"10.1007\/s13311-021-01073-y_bib2","doi-asserted-by":"crossref","unstructured":"Melamed E, Lee MW. Multiple Sclerosis and Cancer: The Ying-Yang Effect of Disease Modifying Therapies. Front Immunol [Internet]. 2020 Jan 10 [cited 2020 Apr 17];10. Available from: https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.02954\/full","DOI":"10.3389\/fimmu.2019.02954"},{"issue":"2","key":"10.1007\/s13311-021-01073-y_bib3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.coi.2007.01.001","article-title":"Humoral immunity, inflammation and cancer","volume":"19","author":"Tan","year":"2007","journal-title":"Curr Opin Immunol."},{"issue":"13","key":"10.1007\/s13311-021-01073-y_bib4","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1212\/01.wnl.0000345366.10455.62","article-title":"Cancer risk among patients with multiple sclerosis and their parents","volume":"72","author":"Bahmanyar","year":"2009","journal-title":"Neurology."},{"issue":"Pt 10","key":"10.1007\/s13311-021-01073-y_bib5","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1093\/brain\/aws148","article-title":"Cancer risk in multiple sclerosis: findings from British Columbia","volume":"135","author":"Kingwell","year":"2012","journal-title":"Canada. Brain J Neurol."},{"issue":"4","key":"10.1007\/s13311-021-01073-y_bib6","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/ijc.21437","article-title":"Cancer risk among patients with multiple sclerosis: a population-based register study","volume":"118","author":"Nielsen","year":"2006","journal-title":"Int J Cancer."},{"key":"10.1007\/s13311-021-01073-y_bib7","doi-asserted-by":"crossref","unstructured":"Midgard R, Glattre E, Gr\u00f8nning M, Riise T, Edland A, Nyland H. Multiple sclerosis and cancer in Norway. A retrospective cohort study. Acta Neurol Scand. 1996 Jun;93(6):411\u20135.","DOI":"10.1111\/j.1600-0404.1996.tb00019.x"},{"key":"10.1007\/s13311-021-01073-y_bib8","doi-asserted-by":"crossref","unstructured":"Hajiebrahimi M, Montgomery S, Burkill S, Bahmanyar S. Risk of Premenopausal and Postmenopausal Breast Cancer among Multiple Sclerosis Patients. PLOS ONE. 2016 Oct 24;11(10):e0165027.","DOI":"10.1371\/journal.pone.0165027"},{"issue":"2","key":"10.1007\/s13311-021-01073-y_bib9","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/ene.12267","article-title":"Increased breast cancer risk for patients with multiple sclerosis: a nationwide population-based cohort study","volume":"21","author":"Sun","year":"2014","journal-title":"Eur J Neurol."},{"key":"10.1007\/s13311-021-01073-y_bib10","article-title":"Risk of cancer among multiple sclerosis patients, siblings, and population controls: A prospective cohort study","volume":"1","author":"Grytten","year":"2019","journal-title":"Mult Scler J."},{"issue":"7","key":"10.1007\/s13311-021-01073-y_bib11","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1007\/s00415-011-5929-9","article-title":"Cancer and multiple sclerosis in the era of disease-modifying treatments","volume":"258","author":"Lebrun","year":"2011","journal-title":"J Neurol."},{"issue":"10","key":"10.1007\/s13311-021-01073-y_bib12","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1136\/jnnp-2013-307238","article-title":"Assessment of cancer risk with \u03b2-interferon treatment for multiple sclerosis","volume":"85","author":"Kingwell","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"4","key":"10.1007\/s13311-021-01073-y_bib13","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1177\/1352458511403642","article-title":"The risk of malignancy is not increased in patients with multiple sclerosis treated with subcutaneous interferon beta-la: analysis of data from clinical trial and post-marketing surveillance settings","volume":"17","author":"Sandberg-Wollheim","year":"2011","journal-title":"Mult Scler Houndmills Basingstoke Engl."},{"issue":"3","key":"10.1007\/s13311-021-01073-y_bib14","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10549-004-2229-4","article-title":"Cancer incidence in multiple sclerosis and effects of immunomodulatory treatments","volume":"89","author":"Achiron","year":"2005","journal-title":"Breast Cancer Res Treat."},{"key":"10.1007\/s13311-021-01073-y_bib15","unstructured":"STROBE Statement: Home [Internet]. [cited 2018 Feb 4]. Available from: https:\/\/www.strobe-statement.org\/index.php?id=strobe-home"},{"key":"10.1007\/s13311-021-01073-y_bib16","unstructured":"Dolladille C, Ederhy S, Sassier M, Cautela J, Thuny F, Cohen AA, et al. Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer. JAMA Oncol [Internet]. 2020 Apr 16 [cited 2020 Apr 18]; Available from: https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2764543"},{"issue":"12","key":"10.1007\/s13311-021-01073-y_bib17","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1007\/s13311-021-01073-y_bib18","doi-asserted-by":"crossref","unstructured":"Chr\u00e9tien B, Lelong-Boulouard V, Chantepie S, Sassier M, Bertho M, Brazo P, et al. Haematologic malignancies associated with clozapine v. all other antipsychotic agents: a pharmacovigilance study in VigiBase\u00ae. Psychol Med. 2020 Feb 10;1\u20138.","DOI":"10.1017\/S0033291720000161"},{"issue":"3","key":"10.1007\/s13311-021-01073-y_bib19","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.therap.2017.08.006","article-title":"Case-non case studies: Principles, methods, bias and interpretation","volume":"73","author":"Faillie","year":"2018","journal-title":"Therapie."},{"key":"10.1007\/s13311-021-01073-y_bib20","doi-asserted-by":"crossref","unstructured":"Chr\u00e9tien B, Dolladille C, Hamel-S\u00e9n\u00e9cal L, Sassier M, Faillie JL, Miremont-Salam\u00e9 G, et al. Comparative study of hypoglycaemia induced by opioids. Is it a class effect? Expert Opin Drug Saf. 2019 Jul 24;1\u20136.","DOI":"10.1080\/14740338.2019.1646246"},{"issue":"2","key":"10.1007\/s13311-021-01073-y_bib21","first-page":"150","article-title":"Review of Statistical Analysis with Missing Data","volume":"16","author":"Mislevy","year":"1991","journal-title":"J Educ Stat."},{"key":"10.1007\/s13311-021-01073-y_bib22","doi-asserted-by":"crossref","unstructured":"Little RJA, Rubin DB. Statistical Analysis with Missing Data, 3rd Edition | Wiley [Internet]. Wiley. 2019 [cited 2020 Apr 18]. (Wiley Series in Probability and Statistics). Available from: https:\/\/www.wiley.com\/en-us\/Statistical+Analysis+with+Missing+Data%2C+3rd+Edition-p-9780470526798","DOI":"10.1002\/9781119482260"},{"key":"10.1007\/s13311-021-01073-y_bib23","doi-asserted-by":"crossref","unstructured":"Sterne JAC, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. The BMJ [Internet]. 2009 Jun 29 [cited 2020 Apr 22];338. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2714692\/","DOI":"10.1136\/bmj.b2393"},{"issue":"1","key":"10.1007\/s13311-021-01073-y_bib24","first-page":"1","article-title":"mice: Multivariate Imputation by Chained Equations in R","volume":"45","author":"van Buuren","year":"2011","journal-title":"J Stat Softw."},{"issue":"4","key":"10.1007\/s13311-021-01073-y_bib25","doi-asserted-by":"crossref","first-page":"e501","DOI":"10.1212\/WNL.0000000000011219","article-title":"Cancer Incidence and Mortality Rates in Multiple Sclerosis: A Matched Cohort Study","volume":"96","author":"Marrie","year":"2021","journal-title":"Neurology."},{"issue":"9","key":"10.1007\/s13311-021-01073-y_bib26","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med."},{"issue":"5","key":"10.1007\/s13311-021-01073-y_bib27","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/ana.25701","article-title":"Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients","volume":"87","author":"Alping","year":"2020","journal-title":"Ann Neurol."},{"issue":"10","key":"10.1007\/s13311-021-01073-y_bib28","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s40263-018-0564-y","article-title":"Cancer Risk in Patients with Multiple Sclerosis: Potential Impact of Disease-Modifying Drugs","volume":"32","author":"Lebrun","year":"2018","journal-title":"CNS Drugs."}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-021-01073-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-021-01073-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923007638?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923007638?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-021-01073-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:42:26Z","timestamp":1761806546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923007638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S1878747923007638"],"URL":"https:\/\/doi.org\/10.1007\/s13311-021-01073-y","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association Between Disease-Modifying Therapies Prescribed to Persons with Multiple Sclerosis and Cancer: a WHO Pharmacovigilance Database Analysis","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-021-01073-y","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}